IOVA Iovance Biotherapeutics Forecast, Technical & Fundamental Analysis
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient... Show more
IOVA is expected to report earnings to fall 31.32% to -13 cents per share on August 06
Q2'26
Est.
$-0.13
Q1'26
Missed
by $0.05
Q4'25
Missed
by $0.01
Q3'25
Beat
by $0.01
Q2'25
Missed
by $0.05
The last earnings report on May 07 showed earnings per share of -18 cents, missing the estimate of -14 cents. With 6.23M shares outstanding, the current market capitalization sits at 2.23B.
A.I. Advisor
published General Information
General Information
a developer of biotechnological products for the treatment of cancer
A.I.dvisor indicates that over the last year, IOVA has been loosely correlated with VIR. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if IOVA jumps, then VIR could also see price increases.
IOVA in upward trend: price rose above 50-day moving average on July 15, 2026
IOVA moved above its 50-day moving average on July 15, 2026 date and that indicates a change from a downward trend to an upward trend. In of 38 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 15, 2026. You may want to consider a long position or call options on IOVA as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IOVA just turned positive on July 15, 2026. Looking at past instances where IOVA's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IOVA advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 158 cases where IOVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for IOVA moved out of overbought territory on July 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IOVA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IOVA broke above its upper Bollinger Band on July 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IOVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.087) is normal, around the industry mean (20.216). P/E Ratio (0.000) is within average values for comparable stocks, (37.938). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.504). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (6.662) is also within normal values, averaging (394.724).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IOVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
